(Reuters) -German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical study titled ‘Low Interventional ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Pfizer bucked the trend of a tepid big pharma Q2 window, raising its full-year profit forecast on the back of strong sales ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

According to the FDA, Comirnaty has the same formulation as the Pfizer COVID-19 vaccine that was previously authorized for emergency use (EUA) in the United States. It will continue to be ...

FDA-approved Comirnaty has the same formulation as the Pfizer COVID-19 vaccine that was previously authorized for emergency use in the U.S.